PR Newswire
WARREN, N.J., July 31, 2018
WARREN, N.J., July 31, 2018 /PRNewswire/ -- Aquestive
Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on identifying, developing and commercializing
differentiated products to address unmet medical needs, today announced that Keith Kendall, Chief
Executive Officer, and John Maxwell, Chief Financial Officer, will present at the 2018 Wedbush
Healthcare Conference to be held in New York, NY on August
14-15.
Aquestive will present on Tuesday, August 14 at 12:45 p.m. Eastern
Daylight Time (EDT). A webcast of the presentation will be available on the "Investors" section of the IR website. For
more information, please visit investors.aquestive.com.
About Aquestive Therapeutics
Aquestive Therapeutics is a specialty pharmaceutical company focused on identifying, developing and
commercializing differentiated products to address unmet medical needs. Aquestive Therapeutics has a late-stage
proprietary product pipeline focused on the treatment of CNS diseases, and is working to advance orally-administered complex
molecules that it believes can be alternatives to invasively-administered standard of care therapies. As the leader in developing
and delivering drugs via its PharmFilm® technology, Aquestive Therapeutics also collaborates with pharmaceutical
partners to bring new molecules to market in differentiated and highly-marketable dosage forms.
Media inquiries:
Christopher Hippolyte
christopher.hippolyte@syneoshealth.com
212-364-0458
Investor inquiries:
Stephanie Carrington
stephanie.carrington@icrinc.com
646-277-1282
View original content:http://www.prnewswire.com/news-releases/aquestive-therapeutics-to-present-at-the-2018-wedbush-healthcare-conference-300688864.html
SOURCE Aquestive Therapeutics